News & Events
Monday December 02, 2019
Neurocrine Biosciences and Xenon Pharmaceuticals Announce Agreement to Develop First-in-Class Treatments for Epilepsy
Neurocrine Biosciences Gains Rights to XEN901, a Clinical Stage Selective Nav1.6 Sodium Channel Inhibitor, Being Developed for the Treatment of Epilepsy Xenon Receives $50 Million Upfront and Up to $1.7 Billion in Potential Development, Regulatory and Commercial Milestone Payments Across All
Tuesday November 26, 2019
Live Audio Webcast will be on December 3, 2019 SAN DIEGO , Nov. 26, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) will present at the Evercore ISI 2 nd Annual HealthCONx Conference at 8:45 a.m. Eastern Time on Tuesday, Dec. 3, 2019 , in Boston .
Tuesday November 12, 2019
Neurocrine Biosciences Publishes Long-Term INGREZZA® (valbenazine) Data in the Journal of Clinical Psychopharmacology Demonstrating Once-Daily 40 mg and 80 mg Capsules Reduced Involuntary Movements in Adults with Tardive Dyskinesia
- Approximately 90% of Patients Treated with INGREZZA in the Open-Label KINECT 4 Phase III Study Achieved a 50% or Greater Improvement in Their Tardive Dyskinesia Symptoms - INGREZZA Continues to Be Well Tolerated Through One Year of Treatment SAN DIEGO , Nov.
Tuesday November 05, 2019
SAN DIEGO , Nov. 5, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that Neurocrine Biosciences management will present at the following investor conferences: Matt Abernethy , Chief Financial Officer, will present at the Credit Suisse 28 th Annual Healthcare
Monday November 04, 2019
INGREZZA® (valbenazine) Third Quarter Net Product Sales of $198.1 Million with Approximately 34,800 TRx Initiated KINECT-HD Phase III Study of Valbenazine to Treat Chorea in Patients with Huntington's Disease SAN DIEGO , Nov. 4, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc.
Wednesday March 13, 2019
Tuesday March 12, 2019
Tuesday February 05, 2019
Tuesday January 29, 2019